These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9443132)

  • 21. [Pharmacological bases of therapy with 5-ASA].
    Beltrán B; Martínez-Cuesta MA; Calatayud S; Hinojosa J; Esplugues JV
    Gastroenterol Hepatol; 1997; 20(6):322-34. PubMed ID: 9296850
    [No Abstract]   [Full Text] [Related]  

  • 22. Sulfasalazine, 5-ASA and acute pancreatitis in crohn's disease.
    Debongnie JC; Dekoninck X
    J Clin Gastroenterol; 1994 Dec; 19(4):348-9. PubMed ID: 7876525
    [No Abstract]   [Full Text] [Related]  

  • 23. Sulfasalazine pneumonitis.
    Yaffe BH; Korelitz BI
    Am J Gastroenterol; 1983 Aug; 78(8):493-4. PubMed ID: 6136183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Massive secretory diarrhea and pseudo-obstruction as the initial presentation of Crohn's disease.
    Carethers JM; McDonnell WM; Owyang C; Scheiman JM
    J Clin Gastroenterol; 1996 Jul; 23(1):55-9. PubMed ID: 8835903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Localized epidermolysis bullosa acquisita of the esophagus in a patient with Crohn's disease.
    Schattenkirchner S; Lémann M; Prost C; Caux F; Guigui B; Cadot M; Bertheau P; Grateau C; Heller M
    Am J Gastroenterol; 1996 Aug; 91(8):1657-9. PubMed ID: 8759686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity.
    Sotolongo RP; Neefe LI; Rudzki C; Ishak KG
    Gastroenterology; 1978 Jul; 75(1):95-9. PubMed ID: 45581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A trial of sulfasalazine as adjunctive therapy in Crohn's disease.
    Singleton JW; Summers RW; Kern F; Becktel JM; Best WR; Hansen RN; Winship DH
    Gastroenterology; 1979 Oct; 77(4 Pt 2):887-97. PubMed ID: 38179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sulfasalazine and renal tubular function: lack of an effect.
    Koutras A; Daum F; Das KM; Markowitz J; Duffy L; Aiges H; Atkinson M; Fisher SE
    J Pediatr Gastroenterol Nutr; 1985 Feb; 4(1):103-6. PubMed ID: 2858519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metastatic Crohn's disease of the lung.
    Minic P; Perisic VN; Minic A
    J Pediatr Gastroenterol Nutr; 1998 Sep; 27(3):338-41. PubMed ID: 9740208
    [No Abstract]   [Full Text] [Related]  

  • 30. [Hepatotoxicity of drugs commonly used in rheumatology].
    Abadia R; Jammet P; Christoforov B; Cremer GA
    Ann Med Interne (Paris); 1985; 136(7):590-600. PubMed ID: 2868682
    [No Abstract]   [Full Text] [Related]  

  • 31. [Clinical effect of salazosulfapyridine (salazopyrin) in Crohn's disease. A controlled double-blind investigation].
    Anthonisen P; Bárány F; Folkenborg O; Holtz A; Jarnum S; Kristensen M; Riis P; Walan A; Worning H
    Ugeskr Laeger; 1974 Aug; 136(32):1798-802. PubMed ID: 4153180
    [No Abstract]   [Full Text] [Related]  

  • 32. [Perianal ulceration as a diagnostic pathway to Crohn's regional enteritis].
    Weidner F; Hornstein OP
    Z Haut Geschlechtskr; 1971 Dec; 46(24):831-7. PubMed ID: 4400564
    [No Abstract]   [Full Text] [Related]  

  • 33. Hypersensitivity reaction to sulfasalazine: skin rash, fever, hepatitis and activated lymphocytes.
    Leroux JL; Ghezail M; Chertok P; Blotman F
    Clin Exp Rheumatol; 1992; 10(4):427. PubMed ID: 1356682
    [No Abstract]   [Full Text] [Related]  

  • 34. Pseudomembranous colitis. A complication of sulfasalazine therapy in a patient with Crohn's colitis.
    Pokorney BH; Nichols TW
    Am J Gastroenterol; 1981 Oct; 76(4):374-6. PubMed ID: 6119900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-inflammatory drug treatment in Crohn's disease.
    Goldstein F; Thornton JJ; Abramson J
    Am J Gastroenterol; 1976 Sep; 66(3):251-8. PubMed ID: 11683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sulfasalazine-induced hepatotoxicity in children with inflammatory bowel disease.
    Boyer DL; Li BU; Fyda JN; Friedman RA
    J Pediatr Gastroenterol Nutr; 1989 May; 8(4):528-32. PubMed ID: 2566669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Granulomatous hepatitis associated with salicylazosulfapyridine therapy.
    Callen JP; Soderstrom RM
    South Med J; 1978 Sep; 71(9):1159-60. PubMed ID: 28568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
    Nakajima H; Munakata A; Yoshida Y
    J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Hanauer S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inflammatory bowel disease (Crohn's disease) in a Spanish patient with pars plana exudates: report of a new case and review of the literature.
    Gorroño-Echebarría MB; Albarrán F; Marcos A; Alvarez-Mon M
    Ocul Immunol Inflamm; 2002 Mar; 10(1):65-8. PubMed ID: 12461705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.